2024 July Update from the EMA Committee for Medicinal Products for Human Use

Did you know that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) publicly releases its monthly meeting highlights? These highlights include medicines recommended for approval, negative opinions on new medicines, recommendations on extensions of therapeutic indication, and more. We are pleased to alert you to this important information, and to specifically feature the hematology-related updates from the committee.

In July 2024:

• Adopted a positive opinion for the biosimilar medicine Ituxredi (rituximab), for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis and pemphigus vulgaris

You can access the full CHMP July 2024 meeting highlights freely; click here.